Bio-Path Holdings to Announce Second Quarter 2022 Financial Results on August 16, 2022

Rhea-AI Summary

Bio-Path Holdings (NASDAQ: BPTH) will host a live conference call on August 16, 2022, at 8:30 a.m. ET to discuss its Q2 financial results and provide a business overview. The call can be accessed by calling (833) 630-1956 domestically or (412) 317-1837 internationally. Additionally, a live audio webcast will be available on the company's website, with an archived version posted two hours afterward. Bio-Path is focused on developing DNAbilize^®, a proprietary RNAi nanoparticle technology, targeting cancer therapies.

Positive

• Live conference call scheduled for August 16, 2022, indicating transparency and engagement with investors.
• Focus on advancing clinical programs, including BP1001 in Phase 2 for blood cancers and upcoming Phase 1 studies for BP1001-A.

Negative

• None.

HOUSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize^® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Tuesday, August 16, 2022 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2022 and to provide a business overview.

To access the live conference call, please call (833) 630-1956 (domestic) or (412) 317-1837 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize^®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and BP1001-A, a drug product modification of prexigebersen, has been cleared by the FDA and Phase 1 studies in solid tumors will commence in 2022. The Company’s second product BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3, in 2022 or first quarter 2023.

For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:
                        
Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com  

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369

FAQ

What is the date of Bio-Path Holdings' next earnings call?

Bio-Path Holdings' next earnings call is scheduled for August 16, 2022.

How can I access the Bio-Path Holdings earnings call?

You can access the earnings call by calling (833) 630-1956 domestically or (412) 317-1837 internationally.

What is the purpose of the upcoming Bio-Path Holdings conference call?

The purpose of the conference call is to report Q2 financial results and provide a business overview.

What technology does Bio-Path Holdings utilize for cancer treatment?

Bio-Path Holdings utilizes its proprietary DNAbilize^® antisense RNAi nanoparticle technology for developing cancer therapies.

What is the ticker symbol for Bio-Path Holdings?

The ticker symbol for Bio-Path Holdings is BPTH.